Kurma Partners and Sunstone Life Science Ventures have led a CHF 20m series-A funding round for Switzerland-based Synendos Therapeutics, a company that develops therapies for central nervous system (CNS) disorders.
Kurma Partners and Sunstone Life Science Ventures have led a CHF 20m series-A funding round for Switzerland-based Synendos Therapeutics, a company that develops therapies for central nervous system (CNS) disorders.